Literature analysis of ocular adverse drug reactions related to dupilumab

FU Ziyi; XIE Tingting; GUO Daihong

doi:10.6039/j.issn.1001-0408.2023.14.16

您当前的位置：

首页 >

文章列表页 >

Literature analysis of ocular adverse drug reactions related to dupilumab

更新时间：2025-09-27

- Literature analysis of ocular adverse drug reactions related to dupilumab
- ZHONGGUO YAOFANG Vol. 34, Issue 14, Pages: 1744-1747(2023)
- 作者机构：
  
  解放军总医院医疗保障中心药剂科，北京　100853
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.14.16
  CLC： R969.3
- Received：29 November 2022，
  
  Revised：2023-06-28，
  
  Accepted：28 June 2023，
  
  Published：30 July 2023
- 稿件说明：
移动端阅览
付子仪,谢婷婷,郭代红.度普利尤单抗致眼部相关不良反应文献分析[J].中国药房,2023,34(14):1744-1747.

FU Ziyi,XIE Tingting,GUO Daihong.Literature analysis of ocular adverse drug reactions related to dupilumab[J].ZHONGGUO YAOFANG,2023,34(14):1744-1747.
付子仪,谢婷婷,郭代红.度普利尤单抗致眼部相关不良反应文献分析[J].中国药房,2023,34(14):1744-1747. DOI： 10.6039/j.issn.1001-0408.2023.14.16.

FU Ziyi,XIE Tingting,GUO Daihong.Literature analysis of ocular adverse drug reactions related to dupilumab[J].ZHONGGUO YAOFANG,2023,34(14):1744-1747. DOI： 10.6039/j.issn.1001-0408.2023.14.16.

摘要

目的

分析度普利尤单抗致眼部相关不良反应（ADR）的临床表现和特点，为临床安全用药提供参考。

方法

检索中国知网、万方数据、维普网、PubMed，收集度普利尤单抗致眼部相关ADR的案例报道，对报告涉及的患者性别、年龄、原患疾病、用药情况、ADR发生时间、主要临床表现、治疗及转归等进行统计分析。

结果

共纳入文献20篇，涉及患者46例，其中男性29例，女性17例，年龄以60岁以下为主。关联性评价结果为“很可能”13例、“可能”33例。所有患者均为使用度普利尤单抗治疗特应性皮炎（AD），无超适应证用药情况。ADR发生时间为用药后2周～2年，以用药后6个月内为主；除3例合并高血压、1例合并慢性阻塞性肺疾病及人类免疫缺陷病毒感染患者同时使用了其他药物外，其余患者均为单用度普利尤单抗。有28例患者有过敏性疾病史，11例有眼部疾病史；眼部相关ADR以结膜炎、葡萄膜炎为主，临床表现主要为结膜充血、肿胀、眼部分泌物等；10例患者发生严重的ADR，包括葡萄膜炎、严重程度的结膜炎及泪点狭窄。45例患者经对症治疗后好转。AD、AD初始症状较重、有过敏性疾病史及眼部基础疾病史可能是度普利尤单抗致眼部相关ADR的高危因素。

结论

临床使用度普利尤单抗前应详细询问患者的过敏性疾病史和眼部基础疾病史，使用时应注意监测患者是否有发生眼内炎症的风险，同时警惕新的、严重的ADR发生，一旦发生ADR应及时给予对症治疗，以保障患者用药安全。

Abstract

OBJECTIVE

To analyze the clinical manifestation and characteristics of ocular adverse drug reaction （ADR） related to dupilumab， so as to provide reference for clinically safe drug use.

METHODS

Retrieved from CNKI， Wanfang data， VIP and PubMed databases， the case reports about ocular ADR caused by dupilumab were collected， and then analyzed statistically in terms of gender， age， primary disease， drug use， occurrence time of ADR， main clinical manifestations， treatment or outcome， etc.

RESULTS

A total of 20 pieces of literature were selected， involving 46 patients， among which there were 29 males and 17 females. Mainly patients were under 60 years old. The results of the association evaluation was given as follows： 13 were “very likely” and 33 were “likely”. All patients were treated with dupilumab for atopic dermatitis （AD） without off-label medication. The occurrence time of ADR was 2 weeks to 2 years after administration， mainly within 6 months after medication. All patients received dupilumab monotherapy except that 3 patients with hypertension and 1 patient with chronic obstructive pulmonary disease and human immunodeficiency virus received other drugs simultaneously. Twenty-eight patients had a history of allergic disease， and 11 patients had a history of eye disease. Ocular ADRs were mainly conjunctivitis and uveitis， and the clinical manifestations mainly included conjunctival congestion， swelling， eye secretions， etc. Ten patients developed severe ADR， including uveitis， severe conjunctivitis， and tear point stenosis； 45 patients were improved after symptomatic treatment. AD， serious initial symptoms of AD， allergic disease and underlying ocular diseases might be the high-risk factors of ocular ADR caused by dupilumab.

CONCLUSIONS

Whether the patient has the history of allergic diseases and basic eye diseases should be asked in detail before clinical use of dupilumab. When using the drug， attention should be paid to monitoring whether the patient has intraocular inflammation， be alert to the occurrence of new or serious ADR， and give timely symptomatic treatment to ensure the safety of drug use.

关键词

Keywords

references

NAKAHARA T ， KIDO-NAKAHARA M ， TSUJI G ， et al . Basics and recent advances in the pathophysiology of atopic dermatitis [J ] . J Dermatol ， 2021 ， 48 （ 2 ）： 130 - 139 .

陈玮，马黎，林伟青 . 度普利尤单抗治疗特应性皮炎患者过程中眼表不良事件研究现状 [J ] . 中华实验眼科杂志， 2022 ， 40 （ 3 ）： 276 - 279 .

中华医学会皮肤性病学分会特应性皮炎研究中心，中华医学会皮肤性病学分会儿童学组 . 度普利尤单抗治疗特应性皮炎专家共识 [J ] . 中华皮肤科杂志， 2022 ， 55 （ 6 ）： 465 - 470 .

PARK S ， LEE J H ， PARK J H ， et al . Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase [J ] . Sci Rep ， 2021 ， 11 （ 1 ）： 14293 .

AYASSE M ， LOCKSHIN B ， DO B K ， et al . A case report of uveitis secondary to dupilumab treatment for atopic dermatitis [J ] . JAAD Case Rep ， 2021 ， 7 ： 98 - 99 .

PADIDAM S ， RAIJI V ， MOORTHY R ， et al . Association of dupilumab with intraocular inflammation [J ] . Ocul Immunol Inflamm ， 2022 ， 30 （ 5 ）： 1068 - 1073 .

MEHTA U ， FARID M . Dupilumab induced limbal stem cell deficiency [J ] . Int Med Case Rep J ， 2021 ， 14 ： 275 - 278 .

LEE D H ， COHEN L M ， YOON M K ， et al . Punctal stenosis associated with dupilumab therapy for atopic dermatitis [J ] . J Dermatolog Treat ， 2021 ， 32 （ 7 ）： 737 - 740 .

FERREIRA S ， TORRES T . Conjunctivitis in patients with atopic dermatitis treated with dupilumab [J ] . Drugs Context ， 2020 ， 9 ： 2020-2-3 .

BARNES A C ， BLANDFORD A D ， PERRY J D . Cicatricial ectropion in a patient treated with dupilumab [J ] . Am J Ophthalmol Case Rep ， 2017 ， 7 ： 120 - 122 .

国家药品不良反应监测中心 . 药品不良反应术语使用指南 [M ] . 北京：国家药品不良反应监测中心， 2016 ： 9 .

陈璐，赵莹，黄江，等 . 特应性皮炎的眼部并发症 [J ] . 中国皮肤性病学杂志， 2021 ， 35 （ 10 ）： 1193 - 1197 .

张佩莲，叶建州 . 度普利尤单抗治疗特应性皮炎的不良反应与防治对策 [EB/OL ] .（ 2022-10-19 ）[ 2023-06-08 ] . https：//kns.cnki.net/kcms2/article/abstract?v https://kns.cnki.net/kcms2/article/abstract?v ＝3uoqIh G8 - C45 S 0 n 9

fL2suRadTyEVl 2 pW9UrhTDCdPD67BObaL_GL2FEK592cthUgQqvGZ1Jcithf8KVMwJT-QsE7iRi Z1 - A4 CU & uniplatform＝NZKPT.

王建琴 . 中国特应性皮炎诊疗指南：2020版解读 [J ] . 皮肤性病诊疗学杂志， 2020 ， 27 （ 5 ）： 359 - 361 .

郭志坚，郑轶，迟立杰，等 . 基于美国FDA不良事件报告系统数据库的度普利尤单抗不良事件信号挖掘及分析 [J ] . 第二军医大学学报， 2021 ， 42 （ 7 ）： 770 - 777 .

TREISTER A D ， KRAFF-COOPER C ， LIO P A . Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis [J ] . JAMA Dermatol ， 2018 ， 154 （ 10 ）： 1208 - 1211 .

LIBERMAN P ， SHIFERA A S ， BERKENSTOCK M . Dupilumab-associated conjunctivitis in patients with atopic dermatitis [J ] . Cornea ， 2020 ， 39 （ 6 ）： 784 - 786 .

WOLLENBERG A ， ARIENS L ， THURAU S ， et al . Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment [J ] . J Allergy Clin Immunol Pract ， 2018 ， 6 （ 5 ）： 1778 - 1780.e1 .

GUEX-CROSIER Y ， DI-LUCCA J ， HÄUSERMANN P ， et al . Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients [J ] . Swiss Med Wkly ， 2021 ， 151 ： w30020 .

韩云凤 . 地塞米松诱导兔眼高眼压的相关研究 [D ] . 石家庄：河北医科大学， 2017 .

Views

249

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Literature analysis of tislelizumab-induced Stevens-Johnson syndrome and toxic epidermal necrolysis

Literature analysis of clinical features and risk factors of drug-induced hypofibrinogenemia

Safety analysis of fondaparinux in pregnancy based on case report literature

Literature analysis of aplastic anemia/pure red cell aplasia induced by pembrolizumab

Literature analysis of cardiotoxicity caused by lidocaine

Related Author

HAN Rui

SHEN Mingxi

YANG Hua

JI Zhaoshuai

WEN Xiao

CAI Le

GAO Ao

ZHU Man

Related Institution

Dept. of Pharmacy， Beijing Tsinghua Changgung Hospital， School of Clinical Medicine， Tsinghua Medicine， Tsinghua University

Quality and Technology Department， No.6 Traditional Chinese Medicine Factory， Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

Dept. of Pharmacy， Tsinghua University Hospital

Dept. of Pharmacy， Medical Support Center， PLA General Hospital

Personalized Drug Therapy Key Laboratory of Sichuan Province/Dept. of Pharmacy， Sichuan Academy of Medical Sciences·Sichuan Provincial People’s Hospital （Affiliated Hospital of University of Electronic Science and Technology of China）

⁰